Scinai Immunotherapeutics is no longer trying to be a late-stage dermatology story. After buying Recipharm Israel for a euro and then letting the PinCell option expire, the residual claim is a two-site Israeli contract manufacturer with a leftover NanoAb research collaboration and almost no cash cushion. The investment debate is whether plant utilization can start covering the new fixed-cost base before the next equity draw. That is a commercial-execution question, not a clinical-readout question, and it is the only frame that matches how the company actually spent the first half of the year.
The mid-year print looks profitable only because of a bargain-purchase accounting gain. Operating loss widened as the Yavne site added people and depreciation faster than recognized work. Cash and restricted cash sat near $3 million at mid-year. Committed customer orders later reached about $3 million, which is still a book of work rather than a completed income statement. The gap between signed purchase orders and cash-covering utilization is the entire equity story.
The next several months resolve a narrower question. Does the unsigned United States clinical-manufacturing program become a definitive contract that actually funds the plants, or does the company keep covering a larger cost base with a standby equity line and warrant overhang? The reverse-split listing repair already happened. The remaining test is commercial conversion, not another pipeline headline.